Clinical Trials Directory

Trials / Terminated

TerminatedNCT02333851

Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)

Comparison of Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
72 (actual)
Sponsor
Hospital Universitario Central de Asturias · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Pilot study to compare the efficacy and safety of a premixed-insulin regimen (70% intermediate insulin and 30% regular insulin) to a basal-bolus insulin regimen (glargine once daily and glulisine before meals) hospitalized patients with type 2 diabetes.

Detailed description

Pilot, randomized, prospective, open-label study admitted to the Hospital with a previous diagnosis of type 2 diabetes or with a blood glucose level on admission greater than 180 mg/dl. Patients were randomized to receive a premixed human insulin formulation with 70% intermediate insulin plus 30% regular insulin (Mixtard 30®, Novo Nordisk) or a basal-bolus regimen with glargine once daily and glulisine before meals (Lantus® and Apidra®, Sanofi-Aventis). The primary outcome of the study was to determine differences in glycemic control between treatment groups as measured by mean daily blood glucose concentration during the hospital stay. Secondary objectives were to determine differences in the percentage of glucose measures between 80 and 180 mg/dl, frequency and severity of hypoglycemic events, total daily insulin use, length of hospital stay and glycemic viability between groups.

Conditions

Interventions

TypeNameDescription
DRUGMixtard 30:70 Novonordisk® twice dailyPremixed insulin twice daily before breakfast and before dinner
DRUGLantus® once daily and Apidra® before mealsInjection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner

Timeline

Start date
2013-06-01
Primary completion
2014-02-01
Completion
2014-02-01
First posted
2015-01-07
Last updated
2015-01-07

Source: ClinicalTrials.gov record NCT02333851. Inclusion in this directory is not an endorsement.